Skip to main content
NCBI home page
NeuroRx logoLink to NeuroRx
. 2012 Sep 5;3(1):69–81. doi: 10.1016/j.nurx.2005.12.006

Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder

Christopher Pittenger 1, John H Krystal 1, Vladimir Coric 1,✉
PMCID: PMC3593363  PMID: 16490414

Summary

Obsessive-compulsive disorder (OCD) is a common psychiatric disorder that produces significant morbidity. The introduction of serotonin reuptake inhibitors in the 1980s represented an important advance in the treatment of OCD. However, few patients show complete remission of their symptoms, and some patients show minimal improvement with existing treatments. We review current treatment strategies and initial data supporting the efficacy of glutamate modulating agents as a novel class of Pharmaceuticals for the treatment of OCD. Functional neuroimaging studies repeatedly reported metabolic hyperactivity in the cortico-striato-thalamo-cortical circuitry in patients with OCD. Recent magnetic resonance spectroscopy studies provide evidence of elevated glutamate levels in several brain regions in patients suffering from OCD. These findings raised the possibility that agents that reduce glutamate hyperactivity or its consequences in the CNS might be efficacious as novel therapeutic interventions. Indeed, initial evidence from our group suggests that the antiglutamatergic agent riluzole (Rilutek), which was developed for the treatment of amyotrophic lateral sclerosis, is effective in treatment-resistant OCD. Case reports suggest that other agents that modulate glutamatergic activity may likewise be effective. This new application of glutamate modulating agents holds promise for the treatment of this disabling and often inadequately treated disease.

Key Words: ALS, obsessive-compulsive disorder, magnetic resonance spectroscopy, glutamate, riluzole, treatment-resistant

References

  • 1.Robins LN, Heizer JE, Weissman MM, Orvaschel H, Gruenberg E, Burke JD, Regier DA. Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psych. 1984;41:949–958. doi: 10.1001/archpsyc.1984.01790210031005. [DOI] [PubMed] [Google Scholar]
  • 2.Karno M, Golding JM, Sorenson SB, Burnam MA. The epidemiology of obsessive-compulsive disorder in five U.S. communities. Arch Gen Psychol. 1988;45:1094–1099. doi: 10.1001/archpsyc.1988.01800360042006. [DOI] [PubMed] [Google Scholar]
  • 3.Jenike MA. Clinical practice. Obsessive-compulsive disorder. N Engl J Med. 2004;350:259–265. doi: 10.1056/NEJMcp031002. [DOI] [PubMed] [Google Scholar]
  • 4.Diagnostic and statistical manual of mental disorders (DSM-IV). Washington, D.C.: American Psychiatric Association, 1994.
  • 5.Mataix-Cols D, Wooderson S, Lawrence N, Brammer MJ, Speckens A, Phillips ML. Distinct neural correlates of washing, checking, and hoarding symptom dimensions in obsessive-compulsive disorder. Arch Gen Psychol. 2004;61:565–576. doi: 10.1001/archpsyc.61.6.564. [DOI] [PubMed] [Google Scholar]
  • 6.Mataix-Cols D, Rosario-Campos MC, Leckman JF. A multidimensional model of obsessive-compulsive disorder. Am J Psychol. 2005;162:228–238. doi: 10.1176/appi.ajp.162.2.228. [DOI] [PubMed] [Google Scholar]
  • 7.Leckman JF, Zhang H, Alsobrook JP, Pauls DL. Symptom dimensions in obsessive-compulsive disorder: towards quantitative phenotypes. Am J Med Genet. 2001;105:28–30. doi: 10.1002/1096-8628(20010108)105:1<28::AID-AJMG1050>3.0.CO;2-8. [DOI] [PubMed] [Google Scholar]
  • 8.Saxena S, Maidment KM. Treatment of compulsive hoarding. J Clin Psychol. 2004;60:1143–1154. doi: 10.1002/jclp.20079. [DOI] [PubMed] [Google Scholar]
  • 9.Husted DS, Shapira NA. A review of the treatment for refractory obsessive-compulsive disorder: from medicine to deep brain stimulation. CNS Spect. 2004;9:833–847. doi: 10.1017/s109285290000225x. [DOI] [PubMed] [Google Scholar]
  • 10.Pallanti S, Hollander E, Goodman WK. A qualitative analysis of nonresponse: management of treatment-refractory obsessive-compulsive disorder. J Clin Psychol. 2004;65(Suppl 14):6–10. [PubMed] [Google Scholar]
  • 11.Coric V, Milanovic S, Wasylink S, Patel P, Malison R, Krystal JH. Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder. Psychopharm (Berl) 2003;167:219–220. doi: 10.1007/s00213-003-1396-z. [DOI] [PubMed] [Google Scholar]
  • 12.Coric V, Taskiran S, Pittenger C, Wasylink S, Mathalon DH, Valentine G, Saksa J, Wu YT, Gueorguieva R, Sanacora G, Malison RT, Krystal JH. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychol 424–428, 2005. [DOI] [PubMed]
  • 13.Abramowitz JS. Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: a quantitative review. J Consult Clin Psychol. 1997;65:44–52. doi: 10.1037/0022-006X.65.1.44. [DOI] [PubMed] [Google Scholar]
  • 14.Greist JH, Bandelow B, Hollander E, Marazziti D, Montgomery SA, Nutt DJ, Okasha A, Swinson RP, Zohar J, World Council on Anxiety WCA recommendations for the long-term treatment of obsessive-compulsive disorder in adults. CNS Spectr. 2003;8(Suppl 1):7–16. doi: 10.1017/s1092852900006908. [DOI] [PubMed] [Google Scholar]
  • 15.Fernandez CE, Lopez-Ibor JJ. Monochlorimipramine in the treatment of psychiatric patients resistant to other therapies. Actas Luso-Españolas de Neurologia Psiquiatria y Ciencias Afines. 1967;26:119–147. [PubMed] [Google Scholar]
  • 16.Reynghe de Voxrie GV. Anafranil (G34586) in obsessive neurosis. Acta Neurolgia Belgica. 1968;68:787–792. [PubMed] [Google Scholar]
  • 17.Fineberg NA, Gale TM. Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int J Neuropsychopharm. 2005;8:107–129. doi: 10.1017/S1461145704004675. [DOI] [PubMed] [Google Scholar]
  • 18.Price LC, Goodman WK, Charney DS, Rasmussen SA, Heninger GR. Treatment of severe obsessive-compulsive disorder with fluvoxamine. Am J Psychol. 1987;144:1059–1061. doi: 10.1176/ajp.144.8.1059. [DOI] [PubMed] [Google Scholar]
  • 19.Goodman WK, Price LJ, Rasmussen SA, Delgado PL, Heninger GR, Charney DS. Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo. Arch Gen Psychol. 1989;46:36–44. doi: 10.1001/archpsyc.1989.01810010038006. [DOI] [PubMed] [Google Scholar]
  • 20.Goodman WK, Price LH, Delgado PL, Palumbo J, Krystal JH, Nagy LM, Rasmussen SA, Heninger GR, Charney DS. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Arch Gen Psychol. 1990;47:577–585. doi: 10.1001/archpsyc.1990.01810180077011. [DOI] [PubMed] [Google Scholar]
  • 21.Jenike MA, Baer L, Minichiello WE, editors. Obsessive-compulsive disorder: practical management. St. Louis, MO: Mosby; 1998. [Google Scholar]
  • 22.Meyer V. Modification of expectations in cases with obsessional rituatls. Behav Res Ther. 1966;4:273–280. doi: 10.1016/0005-7967(66)90023-4. [DOI] [PubMed] [Google Scholar]
  • 23.Baer L, Minichiello WE. Behavior therapy for obsessive-compulsive disorder. In: Jenike MA, Baer L, Minichiello WE, editors. Obsessive-compulsive disorder: practical management. St. Louis, MO: Mosby; 1998. [Google Scholar]
  • 24.Whittal ML, Toordarson DS, McLean PD. Treatment of obsessive-compulsive disorder: cognitive behavioral therapy vs. exposure and response prevention. Behav Res Ther. 2005;43:1559–1576. doi: 10.1016/j.brat.2004.11.012. [DOI] [PubMed] [Google Scholar]
  • 25.March JS, Frances A, Kahn DA, Carpenter D. The expert consensus guideline series: treatment of obsessive-compulsive disorder. J Clin Psychol. 1997;58(Suppl 4):1–72. [Google Scholar]
  • 26.Hembree EA, Riggs DS, Kozak MJ, Franklin ME, Foa EB. Long-term efficacy of exposure and ritual prevention therapy and serotonergic medications for obsessive-compulsive disorder. CNS Spectr. 2003;8:363–371. doi: 10.1017/s1092852900018629. [DOI] [PubMed] [Google Scholar]
  • 27.Albert U, Maina G, Forner F, Bogetto F. Cognitive-behavioral therapy in obsessive-compulsive disorder patients partially unresponsive to SRIs. Eur Neuropsychopharm. 2003;13:S357–S358. doi: 10.1016/S0924-977X(03)92129-8. [DOI] [Google Scholar]
  • 28.Simpson HB, Gorfinkle KS, Liebowitz MR. Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open-label trial. J Clin Psych. 1999;60:584–590. doi: 10.4088/JCP.v60n0904. [DOI] [PubMed] [Google Scholar]
  • 29.Kampman M, Keijsers GPJ, Hoogduin CAL, Verbraak MJPM. Addition of cognitive-behavior therapy for obsessive-compulsive disorder patients non-responding to fluoxetine. Acta Psychol Scand. 2002;106:314–319. doi: 10.1034/j.1600-0447.2002.01261.x. [DOI] [PubMed] [Google Scholar]
  • 30.Pallenti S, Hollander E, Bienstock C, Koran L, Leckman J, Marazziti D, Pato M, Stein D, Zohar J, International Treatment Refractory OCD Consortium Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharm. 2002;5:181–191. doi: 10.1017/S1461145702002900. [DOI] [PubMed] [Google Scholar]
  • 31.Hollander E, Kwon JH, Stein DJ, Broatch J, Rowland CT, Himelein CA. Obsessive-compulsive and spectrum disorders: overview and quality of life issues. J Clin Psychol. 1996;57:3–6. [PubMed] [Google Scholar]
  • 32.Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS. The Yale-Brown obsessive compulsive scale. I. Development, use, and reliability. Arch Gen Psych. 1989;46:1106–1111. doi: 10.1001/archpsyc.1989.01810110048007. [DOI] [PubMed] [Google Scholar]
  • 33.Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, Charney DS. The Yale-Brown obsessive compulsive scale. II. Validity. Arch Gen Psych. 1989;46:1012–1016. doi: 10.1001/archpsyc.1989.01810110054008. [DOI] [PubMed] [Google Scholar]
  • 34.Insel TR, Murphy DL, Cohen RM, Alterman I, Kilts C, Linnoila M. Obsessive-compulsive disorder—a double-blind trial of clomipramine and clorgyline. Arch Gen Psychol. 1983;40:605–612. doi: 10.1001/archpsyc.1983.04390010015002. [DOI] [PubMed] [Google Scholar]
  • 35.Geller DA, Biederman J, Stewart SE, Mullin B, Martin A, Spencer T, Faraone SV. Which SSRI? A meta-analysis of pharamacotherapy trials in pediatric obsessive-compulsive disorder. Am J Psychol. 2003;160:1919–1928. doi: 10.1176/appi.ajp.160.11.1919. [DOI] [PubMed] [Google Scholar]
  • 36.Hollander E, Friedberg J, Wasserman S, Allen A, Birnbaum M, Koran LM. Venlafaxine in treatment-resistant obsessive-compulsive disorder. J Clin Psychol. 2003;64:972–972. doi: 10.4088/jcp.v64n0508. [DOI] [PubMed] [Google Scholar]
  • 37.Albert U, Aguglia E, Maina G, Bogetto F. Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study. J Clin Psychol. 2002;63:1004–1009. doi: 10.4088/jcp.v63n1108. [DOI] [PubMed] [Google Scholar]
  • 38.Denys D, van Megen HJ, van der Wee N, Westenberg HG. A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder. J Clin Psychol. 2004;65:37–43. doi: 10.4088/jcp.v65n0106. [DOI] [PubMed] [Google Scholar]
  • 39.Phelps NJ, Cates ME. The role of venlafaxine in the treatment of obsessive-compulsive disorder. Ann Pharmacother. 2005;39:136–140. doi: 10.1345/aph.1E362. [DOI] [PubMed] [Google Scholar]
  • 40.Pallanti S, Quercioli L, Bruscoli M. Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study. J Clin Psychol. 2004;65:1394–1399. doi: 10.4088/jcp.v65n1015. [DOI] [PubMed] [Google Scholar]
  • 41.Schule C, Laakmann G. Mirtazapine plus citalopram has short term but not longer term benefits over citalopram alone for the symptoms of obsessive compulsive disorder. Evid Based Ment Health. 2005;8:42–42. doi: 10.1136/ebmh.8.2.42. [DOI] [PubMed] [Google Scholar]
  • 42.Koran LM, Gamel NN, Choung HW, Smith EH, Aboujaoude EN. Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation. J Clin Psychol. 2005;66:515–520. [PubMed] [Google Scholar]
  • 43.Koran LM, Faravelli CF, Pallanti S. Intravenous clomipramine in obsessive-compulsive disorder. J Clin Psychopharm. 1994;14:216–218. [PubMed] [Google Scholar]
  • 44.Fallon BA, Liebowitz MR, Campeas R, Schneier FR, Marshall R, Davies S, Goetz D, Klein DF. Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled study. Arch Gen Psychol. 1998;55:918–924. doi: 10.1001/archpsyc.55.10.918. [DOI] [PubMed] [Google Scholar]
  • 45.Pallanti S, Quercioli L, Koran LM. Citalopram intravenous infusion in resistant obsessive-compulsive disorder. J Clin Psychol. 2002;63:796–801. [PubMed] [Google Scholar]
  • 46.Stahl SM. Finding what you are not looking for: strategies for developing novel treatments in psychiatry. NeuroRx. 2006;3:000–000. doi: 10.1016/j.nurx.2005.12.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Leckman JF, Walker DE, Goodman WK, Pauls DL, Cohen DJ. “Just right” perceptions associated with compulsive behavior in Tourette’s syndrome. Am J Psychol. 1994;151:675–680. doi: 10.1176/ajp.151.5.675. [DOI] [PubMed] [Google Scholar]
  • 48.Graybiel AM, Rauch SL. Toward a neurobiology of obsessive-compulsive disorder. Neuron. 2000;28:343–347. doi: 10.1016/S0896-6273(00)00113-6. [DOI] [PubMed] [Google Scholar]
  • 49.Leckman JF, Riddle MA. Tourette’s syndrome: when habit-forming systems form habits of their own? Neuron. 2000;28:349–354. doi: 10.1016/S0896-6273(00)00114-8. [DOI] [PubMed] [Google Scholar]
  • 50.Scahill L, Leckman JF, Schultz RT, Katsovich L, Peterson BS. A placebo-controlled trial of risperidone in Tourette syndrome. Neurology. 2003;60:1130–1135. doi: 10.1212/01.WNL.0000055434.39968.67. [DOI] [PubMed] [Google Scholar]
  • 51.Dion Y, Annable L, Sandor P, Chouinard G. Risperidone in the treatment of Tourette syndrome: a double-blind, placebo-controlled trial. J Clin Psychopharm. 2002;22:31–39. doi: 10.1097/00004714-200202000-00006. [DOI] [PubMed] [Google Scholar]
  • 52.McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: a double-blind placebo-controlled study in patients with and without tics. Arch Gen Psychol. 1994;51:302–308. doi: 10.1001/archpsyc.1994.03950040046006. [DOI] [PubMed] [Google Scholar]
  • 53.McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH. A double-blind placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychol. 2000;57:794–801. doi: 10.1001/archpsyc.57.8.794. [DOI] [PubMed] [Google Scholar]
  • 54.Li X, May RS, Tolbert LC, Jackson WT, Flournoy JM, Baxter LR. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. J Clin Psych. 2005;66:736–743. doi: 10.4088/JCP.v66n0610. [DOI] [PubMed] [Google Scholar]
  • 55.Hollander E, Baldini Rossi N, Sood E, Pallanti S. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2003;6:397–401. doi: 10.1017/S1461145703003730. [DOI] [PubMed] [Google Scholar]
  • 56.Crocq MA, Leclercq P, Guillon MS, Bailey PE. Open-label olanzapine in obsessive-compulsive disorder refractory to antidepressant treatment. Eur Psychol. 2002;17:296–297. doi: 10.1016/S0924-9338(02)00673-9. [DOI] [PubMed] [Google Scholar]
  • 57.D’Amico G, Cedro C, Muscatello MR, Pandolfo G, Di Rosa AE, Zoccali R, La Torre D, Darrigo C, Spina E. Olanzapine augmentation of paroxetine-refractory obsessive-compuslive disorder. Prog Neuropsychopharm Biol Psychol. 2003;27:619–623. doi: 10.1016/S0278-5846(03)00050-2. [DOI] [PubMed] [Google Scholar]
  • 58.Denys D, van Megan H, Westenberg H. Quetiapine addition of serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study. J Clin Psychol. 2002;63:700–703. doi: 10.4088/jcp.v63n0807. [DOI] [PubMed] [Google Scholar]
  • 59.Atmaca M, Kuloglu M, Tezcan E, Gecici O. Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study. Int Clin Psychopharm. 2002;17:115–119. doi: 10.1097/00004850-200205000-00004. [DOI] [PubMed] [Google Scholar]
  • 60.Bystritsky A, Ackerman DL, Rosen RM, Vapnik T, Gorbis E, Maidment KM, Saxena S. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J Clin Psychol. 2004;65:565–568. doi: 10.4088/jcp.v65n0418. [DOI] [PubMed] [Google Scholar]
  • 61.Arias F, Soto JA, Garcia MJ, Rodriguez-Calvin JL, Morales J, Salgado M. Efficacy and tolerance of risperidone addition in serotonin reuptake inhibitors (SRI) treatment for refractory obsessive-compulsive disorder. Eur Neuropsychopharm. 2002;12:S341–S341. doi: 10.1016/S0924-977X(02)80534-X. [DOI] [Google Scholar]
  • 62.Dougherty DD, Rauch SL, Jenike MA. Pharmacotherapy for obsessive-compulsive disorder. J Clin Psychol. 2004;60:1195–1202. doi: 10.1002/jclp.20083. [DOI] [PubMed] [Google Scholar]
  • 63.Koran LM, Aboujaoude E, Bullock KD, Franz B, Gamel N, Elliot M. Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder. J Clin Psychol. 2005;66:353–359. doi: 10.4088/jcp.v66n0312. [DOI] [PubMed] [Google Scholar]
  • 64.Shapira NA, Keck PE, Goldsmith TD, McConville BJ, Eis M, McElroy SL. Open-label pilot study of tramadol hydrochloride in treatment-refractory obsessive-compulsive disorder. Depress Anxiety. 1997;6:170–173. doi: 10.1002/(SICI)1520-6394(1997)6:4<170::AID-DA7>3.0.CO;2-G. [DOI] [PubMed] [Google Scholar]
  • 65.Goldsmith TB, Shapira NA, Keck PE. Rapid remission of OCD with tramadol hydrochloride. Am J Psychol. 1999;156:660–661. doi: 10.1176/ajp.156.4.660a. [DOI] [PubMed] [Google Scholar]
  • 66.Hollander E, Bienstock CA, Koran LM, Pallanti S, Marazziti D, Rasmussen SA, Ravizza L, Benkelfat C, Saxena S, Greenberg BD, Sasson Y, Zohar J. Refractory obsessive-compulsive disorder: state-of-the-art treatment. J Clin Psychol. 2002;63(Suppl 6):20–29. [PubMed] [Google Scholar]
  • 67.Anderson CA, Arcinieagas DB. Neurosurgical interventions for neuropsychiatric syndromes. Curr Psychol Rep. 2004;6:355–363. doi: 10.1007/s11920-004-0022-z. [DOI] [PubMed] [Google Scholar]
  • 68.Barbieri V, Lo Russo G, Francione S, Scarone S, Gambini O. Association of temporal lobe epilepsy and obsessive-compulsive disorder in a patient successfully treated with right temporal lobectomy. Epilepsy Behav. 2005;6:617–619. doi: 10.1016/j.yebeh.2005.02.010. [DOI] [PubMed] [Google Scholar]
  • 69.Guarnieri R, Araujo D, Carlotti GG, Assirati JA, Hallak JE, Velasco TR, Alexandre V, Terra-Bustamante VC, Walz R, Bianchin MM, Wichert-Ana L, Linhares M, Dalmagro CL, Inuzuka LM, Sakamoto AC. Suppression of obsessive-compulsive symptoms after epilepsy surgery. Epilepsy Behav. 2005;7:316–319. doi: 10.1016/j.yebeh.2005.05.024. [DOI] [PubMed] [Google Scholar]
  • 70.Montoya A, Weiss AP, Price BH, Cassem EH, Dougherty DD, Nierenberg AA, Rauch SL, Cosgrove GR. Magnetic resonance imaging-guided stereotactic limbic leukotomy for treatment of intractable psychiatric disease. Neurosurgery. 2002;50:1043–1049. doi: 10.1097/00006123-200205000-00018. [DOI] [PubMed] [Google Scholar]
  • 71.Pressman JD. Last resort: psychosurgery and the limits of med. Cambridge: Cambridge University Press; 2002. [Google Scholar]
  • 72.Tass PA, Klosterkotter J, Schneider F, Lenartz D, Koulousakis A, Sturm V. Obsessive-compulsive disorder: development of demand-controlled deep brain stimulation with methods from stochastic phase resetting. Neuropsychopharmacology. 2003;28(Suppl 1):S27–S34. doi: 10.1038/sj.npp.1300144. [DOI] [PubMed] [Google Scholar]
  • 73.Kopell BH, Greenberg B, Rezai AR. Deep brain stimulation for psychiatric disorders. J Clin Neurophysiol. 2004;21:51–67. doi: 10.1097/00004691-200401000-00007. [DOI] [PubMed] [Google Scholar]
  • 74.Carlson PJ, Singh JB, Zarate CA, Drevets WC, Manji HK. Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targets. NeuroRx. 2006;3:22–41. doi: 10.1016/j.nurx.2005.12.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Abelson JL, Curtis GC, Sagher O, Albucher RC, Harrigan M, Taylor SF, Martis B, Giordani B. Deep brain stimulation for refractory obsessive-compulsive disorder. Biol Psychol. 2005;57:510–516. doi: 10.1016/j.biopsych.2004.11.042. [DOI] [PubMed] [Google Scholar]
  • 76.Martin JL, Barbanoj MJ, Perez V, Sacristan M. Transcranial magnetic stimulation for the treatment of obsessive-compulsive disorder. Cochrane Database Syst Rev. 2003;2:CD003387–CD003387. doi: 10.1002/14651858.CD003387. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Campbell KM, de Lecea L, Severynse DM, Caron MG, McGrath MJ, Sparber SB, Sun LY, Burton FH. OCD-like behaviors caused by a neuro potentiating transgene targeted to cortical and limbic D1+ neurons. J Neurosci. 1999;19:5044–5053. doi: 10.1523/JNEUROSCI.19-12-05044.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Nordstrom EJ, Burton FH. A transgenic model of comorbid Tourette’s syndrome and obsessive-compulsive disorder circuitry. Mol Psychol. 2002;7:617–625. doi: 10.1038/sj.mp.4001144. [DOI] [PubMed] [Google Scholar]
  • 79.Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci. 1997;17:2921–2927. doi: 10.1523/JNEUROSCI.17-08-02921.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Simon AB, Gorman JM. Advances in the treatment of anxiety: targeting glutamate. NeuroRx. 2006;3:57–68. doi: 10.1016/j.nurx.2005.12.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81.McGrath MJ, Campbell KM, Parks CR, Burton FH. Glutamatergic drugs exacerbate symptomatic behavior in a transgenic model of comorbid Tourette’s syndrome and obsessive-compulsive disorder. Brain Res. 2000;877:23–30. doi: 10.1016/S0006-8993(00)02646-9. [DOI] [PubMed] [Google Scholar]
  • 82.Sanacora G, Rothman DL, Mason G, Krystal JH. Clinical studies implementing glutamate neurotransmission in mood disorders. Ann NY Acad Sci. 2003;1003:292–308. doi: 10.1196/annals.1300.018. [DOI] [PubMed] [Google Scholar]
  • 83.Rothman DL, Petroff OA, Behar KL, Mattson RH. Localized 1H NMR measurements of γ-aminobutyric acide in human brain in vivo. Proc Natl Acad Sci USA. 1993;90:5662–5666. doi: 10.1073/pnas.90.12.5662. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84.Sanacora G, Mason GF, Rothman DL, Behar KL, Hyder F, Petroff OA, Berman RM, Charney DS, Krystal JH. Reduced cortical γ-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Arch Gen Psychol. 1999;56:1043–1047. doi: 10.1001/archpsyc.56.11.1043. [DOI] [PubMed] [Google Scholar]
  • 85.Sanacora G, Gueorguieva R, Epperson CN, Wu YT, Appel M, Rothman DL, Krystal JH, Mason GF. Subtype-specific alterations of γ-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychol. 2004;61:705–713. doi: 10.1001/archpsyc.61.7.705. [DOI] [PubMed] [Google Scholar]
  • 86.Ross BD. Biochemical considerations in 1H spectroscopy: glutamate, glutamine, myoinositol and related products. NMR Biomed. 1991;4:59–63. doi: 10.1002/nbm.1940040205. [DOI] [PubMed] [Google Scholar]
  • 87.Rosenberg DR, MacMillan SN, Moore GJ. Brain anatomy and chemistry may predict treatment response in paediatric obsessive-compulsive disorder. Int J Neuorpsychopharm. 2001;4:179–190. doi: 10.1017/S1461145701002401. [DOI] [PubMed] [Google Scholar]
  • 88.Moore GJ, MacMaster FP, Stewart C, Rosenberg DR. Case study: caudate glutamatergic changes with paroxetine therapy for pediatric obsessive-compulsive disorder. J Am Acad Child Adolesc Psychol. 1998;37:663–667. doi: 10.1097/00004583-199806000-00017. [DOI] [PubMed] [Google Scholar]
  • 89.Rosenberg DR, MacMaster FP, Keshavan MS, Fitzgerald KD, Stewart CM, Moore GJ. Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychol. 2000;39:1096–1103. doi: 10.1097/00004583-200009000-00008. [DOI] [PubMed] [Google Scholar]
  • 90.Rosenberg DR, Mirza Y, Russell A, Tang J, Smith JM, Banerjee SP, Bhandari R, Rose M, Ivey J, Boyd C, Moore GJ. Reduced anterior cingulated glutamatergic concentrations in childhood OCD and major depression versus healthy controls. J Am Acad Child Adolesc Psychol. 2004;43:1146–1153. doi: 10.1097/01.chi.0000132812.44664.2d. [DOI] [PubMed] [Google Scholar]
  • 91.Ebert D, Speck O, Konig A, Berger M, Hennig J, Hohagen F. 1H-magnetic resonance spectroscopy in obsessive-compulsive disorder: evidence for neuronal loss in the cingulated gyrus and the right striatum. Psychol Res. 1997;74:173–176. doi: 10.1016/s0925-4927(97)00016-4. [DOI] [PubMed] [Google Scholar]
  • 92.Bartha R, Stein MB, Williamson PC, Drost DJ, Neufeld RW, Carr TJ, Canaran G, Densmore M, Anderson G, Siddiqui AR. A short echo 1H spectroscopy and volumetric MRI study of the corpus striatum in patients with obsessive-compulsive disorder and comparison subjects. Am J Psychol. 1998;155:15840–15891. doi: 10.1176/ajp.155.11.1584. [DOI] [PubMed] [Google Scholar]
  • 93.Ohara K, Isoda H, Suzuki Y, Takehara Y, Ochiai M, Takeda H, Igarashi Y, Ohara K. Proton magnetic resonance spectroscopy of lenticular nuclei in obsessive-compulsive disorder. Psychol Res. 1999;92:83–91. doi: 10.1016/s0925-4927(99)00040-2. [DOI] [PubMed] [Google Scholar]
  • 94.Fitzgerald KD, Moore GJ, Paulson LA, Stewart CM, Rosenberg DR. Proton spectroscopic imaging of the thalamus in treatment-naive pediatric obsessive-compulsive disorder. Biol Psychol. 2000;47:168–170. doi: 10.1016/S0006-3223(99)00297-8. [DOI] [PubMed] [Google Scholar]
  • 95.Rosenberg DR, Amponsah A, Sullivan A, MacMillan S, Moore GJ. Increased medial thalamic choline in pediatric obsessive-compulsive disorder as detected by quantitative in vivo spectroscopic imaging. J Child Neurol. 2001;16:636–641. doi: 10.1177/088307380101600902. [DOI] [PubMed] [Google Scholar]
  • 96.Bolton J, Moore GJ, MacMillan S, Stewart CM, Rosenberg DR. Case study: caudate glutamatergic changes with paroxetine persist after medication discontinuation in pediatric OCD. J Am Acad Child Adolesc Psychol. 2001;40:903–906. doi: 10.1097/00004583-200108000-00011. [DOI] [PubMed] [Google Scholar]
  • 97.Chakrabarty K, Bhattacharyya S, Christopher R, Khanna S. Glutamatergic dysfunction in OCD. Neuropsychopharmacology. 2005;30:1735–1740. doi: 10.1038/sj.npp.1300733. [DOI] [PubMed] [Google Scholar]
  • 98.Greenberg BD, Ziemann U, Corá-Locatelli G, Harmon A, Murphy DL, Keel JC, Wassermann EM. Altered cortical excitability in obsessive-compulsive disorder. Neurology. 2000;54:142–187. doi: 10.1212/WNL.54.1.142. [DOI] [PubMed] [Google Scholar]
  • 99.Hettema JM, Neale MC, Kendler KS. A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am J Psychol. 2001;158:1568–1578. doi: 10.1176/appi.ajp.158.10.1568. [DOI] [PubMed] [Google Scholar]
  • 100.Arnold PD, Rosenberg DR, Mundo E, Tharmalingam S, Kennedy JL, Richter MA. Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study. Psychopharmacology. 2004;174:530–538. doi: 10.1007/s00213-004-1847-1. [DOI] [PubMed] [Google Scholar]
  • 101.Delorme R, Krebs MO, Chabane N, Roy I, Millet B, Mouren-Simeoni MC, Maier W, Bourgeron T, Leboyer M. Frequency and transmission of glutamate receptors GRIK2 and GRIK3 polymorphisms in patients with obsessive-compulsive disorder. Neuroreport. 2004;15:699–702. doi: 10.1097/00001756-200403220-00025. [DOI] [PubMed] [Google Scholar]
  • 102.Aventis: Rilutek. In: Physician’s desk reference. Montvale, NJ: Thompson Healthcare, 2004.
  • 103.Urbani A, Belluzzi O. Riluzole inhibits the persistent sodium current in mammalian CNS neurons. Eur J Neurosci. 2000;12:3567–3574. doi: 10.1046/j.1460-9568.2000.00242.x. [DOI] [PubMed] [Google Scholar]
  • 104.Wang SJ, Wang KY, Wang WC. Mechanisms underlying the riluzole inhibiton of glutamate release from rat cerebral cortex nerve terminals (synaptosomes) Neuroscience. 2004;125:191–201. doi: 10.1016/j.neuroscience.2004.01.019. [DOI] [PubMed] [Google Scholar]
  • 105.Xu L, Enyeart JA, Enyeart JJ. Neuroprotective agent riluzole dramatically slows in activation of Kv1.4 potassium channels by a voltage-dependent oxidative mechanism. J Pharm Exp Ther. 2001;299:227–237. [PubMed] [Google Scholar]
  • 106.Frizzo ME, Dall’Onder LP, Dalcin KB, Souza DO. Riluzole enhances glutamate uptake in rat astrocyte cultures. Cell Mol Neurobiol. 2004;24:123–128. doi: 10.1023/B:CEMN.0000012717.37839.07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 107.Jehle T, Bauer J, Blauth E, Hummel A, Darstein M, Freiman TM, Feuerstein TJ. Effects of riluzole on electrically evoked neuro-transmitter release. Br J Pharmacol. 2000;130:1227–1234. doi: 10.1038/sj.bjp.0703424. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 108.Mohammadi B, Krampfl K, Moschref H, Dengler R, Butler J. Interaction of the neuro protective drug riluzole with GABA(A) and glycine receptor channels. Eur J Pharmacol. 2001;415:135–140. doi: 10.1016/S0014-2999(01)00847-0. [DOI] [PubMed] [Google Scholar]
  • 109.He Y, Benz A, Fu T, Wang M, Covey DF, Zorumski CF, Mennerick S. Neuroprotective agent riluzole potentiates postsynaptic GABA(A) receptor function. Neuropharmacology. 2002;42:199–209. doi: 10.1016/S0028-3908(01)00175-7. [DOI] [PubMed] [Google Scholar]
  • 110.Katoh-Semba R, Asano T, Ueda H, Morishita R, Takeuchi IK, Inaguma Y, Kato K. Riluzole enhances expression of brain-derived neurotrophic factor with consequent proliferation of granule precursor cells in the rat hippocampus. FASEB J. 2002;16:1328–1330. doi: 10.1096/fj.02-0143fje. [DOI] [PubMed] [Google Scholar]
  • 111.Mizuta I, Ohta M, Ohta K, Nishimura M, Mizuta E, Kuno S. Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor, and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes. Neurosci Lett. 2001;310:117–120. doi: 10.1016/S0304-3940(01)02098-5. [DOI] [PubMed] [Google Scholar]
  • 112.Zarate CA, Payne JL, Quiroz J, Sport J, Denicoff KK, Luckenbaugh D, Charney DS, Manji HK. An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychol. 2004;161:171–174. doi: 10.1176/appi.ajp.161.1.171. [DOI] [PubMed] [Google Scholar]
  • 113.Sanacora G, Kendell SF, Fenton L, Coric V, Krystal JH. Riluzole augmentation for treatment-resistant depression. Am J Psychol. 2004;161:2132–2132. doi: 10.1176/appi.ajp.161.11.2132. [DOI] [PubMed] [Google Scholar]
  • 114.Singh J, Zarate CA, Krystal AD. Case report: successful riluzole augmentation therapy in treatment-resistant bipolar depression following the development of rash with lamotrigine. Psychopharmacology. 2004;173:227–228. doi: 10.1007/s00213-003-1756-8. [DOI] [PubMed] [Google Scholar]
  • 115.Zarate CA, Quiroz JA, Singh JB, Denicoff KD, De Jesus G, Luckenbaugh DA, Charney DS, Manji HK. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychol. 2005;57:430–432. doi: 10.1016/j.biopsych.2004.11.023. [DOI] [PubMed] [Google Scholar]
  • 116.Kumar TC, Khanna S. Lamotrigine augmentation of serotonin re-uptake inhibitors in obsessive-compulsive disorder. Aust NZ J Psychol. 2000;34:527–528. doi: 10.1080/j.1440-1614.2000.0751c.x. [DOI] [PubMed] [Google Scholar]
  • 117.Moran MM, McFarland K, Melendez RI, Kalivas PW, Seamans JK. Cystine/glutamate exchange regulates metabolic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking. J Neurosci. 2005;25:6389–6393. doi: 10.1523/JNEUROSCI.1007-05.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 118.Baker DA, McFarland K, Lake RW, Shen H, Tang XC, Toda S, Kalivas PW. Neuroadaptation s in cystine-glutamate exchange underlie cocaine relapse. Nat Neurosci. 2003;6:743–749. doi: 10.1038/nn1069. [DOI] [PubMed] [Google Scholar]
  • 119.Murphy TH, Miyamoto M, Sastre A, Schnaar RL, Coyle JT. Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress. Neuron. 1989;2:1547–1558. doi: 10.1016/0896-6273(89)90043-3. [DOI] [PubMed] [Google Scholar]
  • 120.Oka A, Belliveau MJ, Rosenberg PA, Volpe JJ. Vulnerability of oligodendroglia to glutamate: pharmacology, mechanisms, and prevention. J Neurosci. 1993;13:1441–1453. doi: 10.1523/JNEUROSCI.13-04-01441.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 121.Noble M, Mayer-Proschel M. On the track of cell survival pharmaceuticals in the oligodendrocyte type-2 astrocyte lineage. Perspect Dev Neurobiol. 1996;3:121–131. [PubMed] [Google Scholar]
  • 122.Han D, Sen CK, Roy S, Kobayashi MS, Tritschler HJ, Packer L. Protection against glutamte-induced cytotoxicity in C6 glial cells by thiol antioxidants. Am J Physiol (Lond) 1997;273:R1771–R1778. doi: 10.1152/ajpregu.1997.273.5.R1771. [DOI] [PubMed] [Google Scholar]
  • 123.Lafleur DL, Pittenger C, Kelmendi B, Gardner T, Wasylink S, Malison RT, Sanacora G, Krystal JH, Coric V. N-acety Icy steine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharm (Berl) 2006;184:254–256. doi: 10.1007/s00213-005-0246-6. [DOI] [PubMed] [Google Scholar]
  • 124.Pittinger C, Krystal JH, Coric V. Initial evidence of the beneficial effects of glutamate modulating agents in the treatment of self-injurious behavior associated with borderline personality disorder. J Clin Psychol. 2005;66:1492–1493. doi: 10.4088/jcp.v66n1121d. [DOI] [PubMed] [Google Scholar]
  • 125.Ozkara C, Ozmen M, Erdogan A, Yalug I. Topiramate related obsessive-compulsive disorder. Eur Psychol. 2005;20:78–79. doi: 10.1016/j.eurpsy.2004.09.015. [DOI] [PubMed] [Google Scholar]
  • 126.Gerdeman G, Lovinger DM. CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J Neurophysiol. 2001;85:468–471. doi: 10.1152/jn.2001.85.1.468. [DOI] [PubMed] [Google Scholar]
  • 127.Saxena S, Brody AL, Schwartz JM, Baxter LR. Neuroimaging and frontal-subcortical circuitry in obsessive-compulsive disorder. Br J Psychiatry Suppl. 1998;35:26–37. [PubMed] [Google Scholar]
  • 128.Cavus I, Kasoff WS, Cassaday MP, Jacob R, Guerguieva R, Sherwin RS, Krystal JH, Spencer DD, Abi-Saab WM. Extracellular metabolites in the cortex and hippocampus of epileptic patients. Ann Neurol. 2005;57:226–235. doi: 10.1002/ana.20380. [DOI] [PubMed] [Google Scholar]
  • 129.Pittenger C, Naungayan C, Kendall S, Coric V, Malison R, Krystal JH, Sanacora G. Visual hallucinations from the addition of riluzole to memantine and bupropion. J Clin Psychopharmol, in press. [DOI] [PubMed]
  • 130.Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, Jin L, Dykes Hoberg M, Vidensky S, Chung DS, Toan SV, Bruijn LI, Su ZZ, Gupta P, Fisher PB. β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature. 2005;433:73–77. doi: 10.1038/nature03180. [DOI] [PubMed] [Google Scholar]

Articles from NeuroRx are provided here courtesy of Am. Soc. for Experimental NeuroTherapeutics

RESOURCES